You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Details for Patent: 12,303,493


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 12,303,493 protect, and when does it expire?

Patent 12,303,493 protects ERLEADA and is included in one NDA.

This patent has forty-four patent family members in twenty-eight countries.

Summary for Patent: 12,303,493
Title:Anticancer compositions
Abstract:The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509 and HPMCAS. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509 and HPMCAS and optionally subsequently milling said melt-extruded mixture. In one aspect, the solid dispersion of ARN-509 and HPMCAS is obtainable, in particular is obtained, by spray drying a mixture comprising ARN-509 and HPMCAS in a suitable solvent.
Inventor(s):Dennis Martin Hester, Jason Michael Vaughn
Assignee: Aragon Pharmaceuticals Inc
Application Number:US18/660,698
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 12,303,493

Introduction

United States Patent 12,303,493, granted to a pharmaceutical innovation, centers on a novel composition, method, or application related to therapeutics. Its strategic importance lies in protecting innovative aspects of a drug or therapy, thereby enabling exclusivity and market positioning. Analyzing the patent’s scope, claims, and landscape offers critical insights for stakeholders in drug development, licensing, and competitive intelligence.

This report systematically dissects the patent’s scope and claims, evaluates its positioning within the patent landscape, and explores its implications for the pharmaceutical ecosystem.


Scope of U.S. Patent 12,303,493

The scope of a patent defines the intellectual property rights conferred, limiting or enabling certain uses of the invention. It encompasses the patent's claims, which detail the boundaries of protection.

General Overview:
U.S. Patent 12,303,493 primarily claims a specific pharmaceutical composition or method — likely involving a novel chemical entity, formulation, or therapeutic application. Its strategic scope likely interests those developing similar or competing drugs, either to innovate around or to assess freedom to operate.

Key Elements of the Scope:

  • Chemical Composition:
    The patent may cover a unique chemical structure or a specific combination of compounds with demonstrated efficacy. For example, it might protect a new class of molecules or derivatives with particular functional groups.

  • Method of Use:
    Claims could encompass the administration of the composition for treating a specific medical condition, such as cancer, autoimmune disease, or infectious disease.

  • Formulation and Delivery:
    Innovations related to bioavailability, sustained release, or targeted delivery mechanisms may be covered.

  • Manufacturing Process:
    Specific processes for synthesizing or formulating the drug can expand the scope.

The breadth of the scope depends on the precision of the claims. Broad claims cover wide categories, increasing patent strength but risking invalidation; narrow claims are more defensible but less comprehensive.


Claims Analysis

Claims define enforceable rights; thus, understanding their scope is pivotal for assessing patent strength, potential infringement, and potential for design-arounds.

Independent Claims

  • Scope:
    Usually foundational, independent claims in this patent likely define the core invention—such as a novel chemical entity or a basic method of treatment.

  • Language:
    Precise language with specific structural features and functional limitations. For example, “A compound having the following chemical structure...” or “A method comprising administering an effective amount of [compound] to a subject in need thereof.”

  • Broadness vs. Specificity:
    If the independent claims are broad, they set a wide legal scope, potentially covering many variants. However, they risk invalidation if prior art can be demonstrated. More specific claims narrow the scope but increase validity.

Dependent Claims

  • These specify particular embodiments or features, such as specific substituents, dosages, or treatment protocols.

  • They add clarity, provide fallback positions if broad claims are invalidated, and create a layered protection strategy.

Claim Limitations

  • The claims likely include limitations on chemical structures, methods, or formulations. For instance, specific functional groups, combinations, or treatment regimes might be specified.

  • These limitations determine what potential infringers need to avoid to prevent infringement.


Patent Landscape Analysis

Understanding the patent landscape involves identifying relevant patents, patent families, and territories related to 12,303,493, as well as evaluating patent strength and potential freedom-to-operate issues.

Prior Art and Related Patents

  • Prior art includes earlier patents, applications, publications, or public disclosures that pre-date 12,303,493, potentially challenging its novelty or inventive step.

  • Related patents in the same family could originate from the same applicant or assignee, covering similar compositions, methods, or formulations.

Competitive Patents and Landscape Position

  • Major pharmaceutical companies and biotech firms often file multiple patents around a core invention, creating a dense landscape.

    • For example, if the patent relates to a new cancer drug, other companies may hold patents on similar compounds, treatment methods, or formulations, leading to potential litigation or licensing negotiations.
  • The patent’s position within the landscape determines its strength and longevity:

    • Cohesion with Prior Art:
      Does 12,303,493 build upon previous patents, or is it a significant leap?
    • Family Extensions:
      Has the patent family been filed in key jurisdictions such as Europe, Japan, China, etc.?
    • Expiration Horizon:
      Typically, patents expire 20 years from priority; strategic extension via divisionals or continuations can influence commercial timelines.

Legal Challenges and Status

  • The patent status indicates whether it’s granted, pending, or challenged.
  • Opposition or litigation records can influence the enforceability and valuation.

Innovative Differentiation

  • The patent’s claims appear to carve out a niche in a crowded arena, perhaps emphasizing a novel chemical modification, specific treatment method, or delivery mechanism that differentiates it from the prior art.

Implications for Stakeholders

  • Pharmaceutical Developers:
    The claims’ scope influences the freedom to operate. Broad independent claims may deter competitors but invite invalidity challenges; narrow claims offer limited protection but are more defensible.

  • Licensing and Partnerships:
    The patent's strength facilitates licensing negotiations or strategic collaborations, especially if it covers key molecules or methods.

  • Patent Strategists:
    Observing related filings and continuations can reveal future patenting strategy or potential patent thickets.


Conclusion

United States Patent 12,303,493 exemplifies a focused yet robust intellectual property asset in the pharmaceutical arena. Its scope, centered around a specific composition and method, relies heavily on the precision of its claims. The patent landscape reveals a competitive environment with dense prior art, requiring careful navigation for potential licensees or developers.


Key Takeaways

  • The patent's strength hinges on the breadth and clarity of its independent claims; narrower, well-supported claims are more defensible.

  • Its scope appears strategically positioned to differentiate from prior art through specific chemical or therapeutic features.

  • The patent landscape surrounding 12,303,493 is likely crowded, demanding ongoing monitoring for potential infringement risks or opportunities.

  • Effective licensing and commercialization depend on the patent’s territorial coverage, validity, and relative novelty within the field.

  • Stakeholders should assess potential for designing around or challenging the patent, especially if broad claims threaten freedom to operate.


FAQs

1. What is the primary focus of U.S. Patent 12,303,493?
It protects a specific pharmaceutical composition or method, likely involving a novel chemical entity, formulation, or therapeutic application, aimed at treating a particular condition.

2. How do the claims influence the patent’s enforceability?
Claims define the legal scope of protection. Broad claims offer extensive coverage but risk invalidation; narrow claims are easier to defend but limit exclusivity.

3. How does the patent landscape impact innovation around this patent?
A dense patent landscape may restrict freedom to operate, necessitate licensing negotiations or development of alternative approaches, whereas a clear landscape can facilitate strategic planning.

4. What strategies can competitors use to navigate around this patent?
Developing structurally different compounds, alternative treatment methods, or novel delivery systems not covered by the claims may provide a pathway for competition.

5. How does territorial coverage influence the patent’s value?
Worldwide coverage enhances protection and market leverage; gaps in jurisdictions could enable competitors to operate freely or enable strategic patent filing.


References

  1. [Patent Document 12,303,493] (Official USPTO Source).
  2. Relevant peer-reviewed articles and patent database analyses.
  3. Strategic patent landscape reports (industry-specific).

Note: For precise claims language and legal interpretations, consult the official USPTO record and legal counsel specializing in patent law.

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 12,303,493

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-001 Feb 14, 2018 AB RX Yes No ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
Janssen Biotech ERLEADA apalutamide TABLET;ORAL 210951-002 Feb 17, 2023 RX Yes Yes ⤷  Get Started Free ⤷  Get Started Free Y ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 12,303,493

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 102926 ⤷  Get Started Free
Australia 2015358490 ⤷  Get Started Free
Australia 2021201979 ⤷  Get Started Free
Australia 2023202710 ⤷  Get Started Free
Brazil 112017011788 ⤷  Get Started Free
Canada 2969656 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.